||Last Updated: Nov 17th, 2006 - 22:35:04
Regulatory Approval for New Cotara(R) Brain Cancer Clinical Trial
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage products for the treatment of cancer and hepatitis C virus infection, today announced that it has received regulatory approval in India for a new clinical trial of its lead tumor necrosis therapy (TNT) agent Cotara(R). The trial is designed to test the safety and efficacy of Cotara in patients with glioblastoma multiforme, a deadly form of brain cancer. Cotara is currently being studied in a multi-center U.S. glioblastoma trial. Previous studies using Cotara to treat brain cancer have produced encouraging results, and Peregrine expects that positive data from this trial in combination with data from the ongoing U.S. clinical trial should provide the foundation for planning the future development and commercialization of Cotara.
Oct 13, 2006, 01:17
Lead exposure linked with brain cancer
People who are routinely exposed to lead on the job are 50 percent more likely to die from brain cancer than people who are not exposed, according to a University of Rochester Medical Center study.
Aug 29, 2006, 03:13
Synthetic scorpion venom delivers radioactive iodine to malignant gliomas
A new method of delivering a dose of radioactive iodine – using a man-made version of scorpion venom as a carrier – targets deadly brain tumors called gliomas without affecting neighboring tissue or body organs. After a Phase I clinical trial conducted in 18 patients showed the approach to be safe, a larger Phase II trial is underway to assess the effectiveness of multiple doses.
Jul 30, 2006, 02:45
Chromosomal Testing Can Determine Brain Tumor Therapy
A trial involving two types of rare, malignant but treatable brain tumors shows that missing portions of two chromosomes can predict which patients will likely do better with therapy. The results, says senior author Walter J. Curran Jr., M.D., professor and chair of radiation oncology at Jefferson Medical College of Thomas Jefferson University in Philadelphia, represents a paradigm shift in treating such tumors, known as gliomas.
Jul 1, 2006, 03:39
Motexafin gadolinium extends cognitive function in patients with brain metastases
The drug motexafin gadolinium (Xcytrin®), based on a molecule developed by chemists at The University of Texas at Austin, shows significant promise in prolonging cognitive function in patients with non-small cell lung cancer that has metastasized to the brain.
Jun 6, 2006, 14:44
New vaccine to fight glioblastoma multiforme developed
A vaccine to fight an aggressive form of brain tumour has been developed by US scientists, who say it can delay progression of the cancer.
May 2, 2006, 22:40
New mouse model that closely mimics human medulloblastoma
Researchers have created a mouse model that closely mimics human medulloblastoma, the most common type of childhood brain tumor. The new model, which was created by knocking out a key component of the DNA repair machinery, will aid in exploring the genetic roots of this deadly brain cancer. The researchers, led by Howard Hughes Medical Institute investigator Frederick W. Alt, published their findings the week of April 24, 2006, in the early online edition of the Proceedings of the National Academy of Sciences. Catherine Yan, who is in Alt's laboratory at Children's Hospital Boston, was lead author of the article. Other co-authors were from Brigham & Women's Hospital, CBR Institute of Biomedical Research, Children's Hospital and Dana-Farber Cancer Institute, all of Harvard Medical School.
Apr 28, 2006, 01:38
Immune response protects against brain tumor development
In their quest to determine whether immune system surveillance guards against brain tumor development, researchers at The University of Texas M. D. Anderson Cancer Center have found that allergies and asthma that stimulate inflammation may be protective, but use of antihistamines to control the inflammation could eliminate that protection.
Apr 3, 2006, 07:02
Long mobile use could cause brain tumours - New Study
Using a cell phone for long periods could lead to malignant brain tumours, says a new study contradicting earlier findings which found no such link.
Apr 3, 2006, 07:01
Donepezil helps cognitive function in brain tumor patients after radiation
A drug that is marketed to treat Alzheimer's disease also improves cognitive function, mood and quality of life in brain tumor patients following radiation therapy, according to a research team at Wake Forest University Baptist Medical Center.
Mar 19, 2006, 20:50
Infections could trigger some adult brain tumours
Infections could play a key role in triggering certain types of adult brain cancer, according to results from a new statistical analysis of the disease.
Jan 24, 2006, 15:54
Mobiles not linked to increased risk of brain tumours
Mobile phones are not associated with an increased risk of the most common type of brain tumour, finds the first UK study of the relationship between mobile phone use and risk of glioma. The results are published online by the BMJ.
Jan 21, 2006, 16:21
No link between mobile phones and glioma
Mobile phones are not associated with an increased risk of the most common type of brain tumour, finds the first UK study of the relationship between mobile phone use and risk of glioma. The results are published online by the BMJ today.
Jan 20, 2006, 15:14
Discovery could change the way doctors treat glioblastomas
Researchers at UCLA's Jonsson Cancer have identified key characteristics in certain deadly brain tumors that make them 51 times more likely to respond to a specific class of drugs than tumors in which the molecular signature is absent. The discovery of the telltale molecular signature — the expression of a mutant protein and the presence of a tumor suppressor protein called PTEN — will allow researchers to identify patients who are likely to respond to the drug treatment before they undergo therapies that are not likely to work, said Dr. Paul Mischel, a UCLA associate professor of pathology and laboratory medicine and a Jonsson Cancer Center researcher.
Nov 11, 2005, 00:46
Glioblastoma Gene Variations Can Predict Treatment Response
Screening glioblastoma brain tumors for two gene variations can reliably predict which tumors will respond to a specific class of drugs, a new study shows. The findings may lead to improved treatment for this devastating disease. The study was funded in part by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), and appears in the November 10, 2005, issue of the New England Journal of Medicine. Glioblastomas are the most common malignant brain tumors in adults, and they are notoriously difficult to treat successfully. "The survival with glioblastoma is usually a year on average, and that hasn't improved in a while, so this is a very serious and challenging disease," says Paul Mischel, M.D., of the David Geffen School of Medicine and Jonsson Comprehensive Cancer Center at the University of California , Los Angeles (UCLA), who led the study. While drugs are available to help treat glioblastoma, they often have minimal effect, and doctors usually have time to try only one or two treatments before the disease causes severe impairment. Glioblastomas feature many genetic variations that affect their response to different treatments. Researchers are trying to identify these genetic factors and to tease apart how they affect the disease in order to determine which patients are the most likely to benefit from specific drugs.
Nov 11, 2005, 00:20
Evidence-based Review on Radiation for Brain Tumors
The American Society for Therapeutic Radiology and Oncology gathered a panel of experts to compile and analyze existing studies on the use of radiosurgery, a specialized type of external beam radiation therapy that pinpoints high doses of radiation to treat brain tumors. The panel has developed evidence-based reviews that consolidate the information available and identify questions to be answered in future research. The two new reviews are published in the September 1, 2005 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.
Sep 11, 2005, 21:41
P-gp system let JV-1-36 pass into the brain to treat malignant glioblastomas
A compound that kills cancer can sneak past the blood brain barrier, which protects the brain from foreign substances, to do its work in fighting a particularly invasive brain cancer, according to a new Saint Louis University animal study published in the Proceedings of the National Academy of Sciences Online Early Edition the week of Aug. 22.
Aug 23, 2005, 19:56
Combined gene therapy can eliminate glioblastoma multiforme
Despite aggressive treatment, glioblastoma multiforme (GBM) – the most common and deadly of brain cancers – usually claims the lives of its victims within six to 12 months of diagnosis. Because GBM is so aggressive, the disease has been the target of a number of laboratory and clinical studies investigating the effectiveness of gene therapy to deliver novel therapies to the brain. In laboratory studies, this type of gene therapy has proved almost completely effective. But in clinical trials, it has had limited effectiveness.
Aug 15, 2005, 17:44
Vaccine to target resistance-related antigen in Brain tumours
In the August issue of the journal Oncogene, researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute describe a molecular mechanism that appears to make malignant brain tumors more vulnerable to chemotherapy after they have been treated with the dendritic cell vaccine.
Jun 14, 2005, 06:24
First Study to Prove association of Mobile Phones with Brain Tumours
The findings are based on a sample of over 1400 adults aged between 20 and 80, living in the centre of Sweden. All of them had been diagnosed with a malignant or benign brain tumour between January 1997 and June 2000.
May 18, 2005, 14:55
Chromosome Deletion Predicts Outcome in Neuroblastoma Patients
Researchers from the Children's Hospital of Philadelphia and the Children's Oncology Group found that patients with neuroblastoma who are missing a portion of one of their chromosomes are less likely to survive than those without this genetic aberration, providing potentially important information to guide therapy.
May 18, 2005, 01:45
Pituitary Gland Tumors Are Often Misdiagnosed
A recent study found that tumors of the pituitary gland are more common than many health care professionals realize, with national prevalence rates averaging 16.7 percent.
May 1, 2005, 21:04
CHMP Issues Positive Opinion for First-line Use of Temozolomide in the treatment of Glioblastoma Multiforme
Schering-Plough Corporation (NYSE: SGP - News) today reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of TEMODAL® (temozolomide) Capsules for first-line use in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM), the most common form of brain cancer. The CHMP recommendation serves as the basis for a European Commission approval.
Apr 24, 2005, 08:22
No Link Between Cell Phone and Brain Tumors
A new study has found no link between use of cell phones and the risk of developing a brain tumor.
Apr 12, 2005, 18:02
Viruses May Treat Brain Tumors
New research shows that a virus designed to kill cancer cells can significantly increase the survival of mice with an incurable human brain tumor, even in some animals with advanced disease.
Apr 8, 2005, 01:36
Errant neuro-developmental gene implicated in brain cancer
A gene that's normally silenced after contributing to brain development was found to be expressed in cells from medulloblastoma, the most common form of pediatric brain malignancy in children, scientists report in an article published in the February 1 issue of the journal Cancer Research. In their study, the scientists discovered that multiple extra copies of the gene, called OTX2, had been switched back on among tumor cells removed from patients with medulloblastoma brain tumors. In the United States, medulloblastoma accounts for approximately 30 percent of all pediatric brain tumors.
Feb 3, 2005, 00:49